HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin

This article was originally published in The Rose Sheet

Executive Summary

Business "simplification" initiative in 2006 intended to benefit direct-seller's sales force will result in $15 mil.-$25 mil. in restructuring charges to be taken within the next few quarters, Nu Skin announces Nov. 30. As part of its strategy, company plans to "eliminate organizational redundancies, revamp administrative support functions, prioritize investments to favor profitable initiatives and markets, and increase efficiencies in our supply chain process." In addition to revenue shortfall, charges also will cause negative impact on earnings per share, firm notes. Strength of U.S. dollar against other currencies also has led company to revise fourth quarter sales estimates to $285 mil.-$290 mil. versus prior expectations of $300 mil.-$305 mil. (1"The Rose Sheet" Oct. 10, 2005, In Brief). Decline in revenue is anticipated to reduce earnings per share in Q4 by about $.03, firm adds...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel